S-adenosyl-L-methionine (hereinafter referred to as SAMe) is a metabolite of sulfur-containing amino acid-methionine (methionine) combined with ATP-adenosinetriphosphate (ATP-adenosinetriphosphate), the main energy substance in the human body. SAMe is neither a herbal medicine nor a Not a hormone, it is a particulate molecule that participates in more than 200 biochemical reactions in the human body.
SAMe can be used to treat depression, arthritis, liver dysfunction and other diseases, and it is also an advanced health care drug for the prevention of cancer, cardiovascular disease and anti-aging. It has the characteristics of fast onset, small side effects, safety and reliability.
SAMe has been on the European pharmaceutical market since the 1970s, when it was used to treat arthritis. Its efficacy in osteoarthritis is comparable to ibuprofen and naproxen, but with fewer side effects and quicker results. However, due to the high price of SAMe, it is difficult for consumers to accept it, and there are many varieties of anti-inflammatory drugs abroad, so it does not have an advantage in the market.
The application focus of SAMe in different countries is different: in Europe and the United States, it is widely used as an antidepressant drug and health care product; while in my country, its clinical application is mainly concentrated in liver diseases. my country is a major hepatitis epidemic country. According to statistics, there is no biological drug that can truly improve the metabolism of liver cells in my country. Therefore, it is of great significance to develop SAMe drugs in China.
With the improvement of people's quality of life and the renewal of health concepts, the demand for SAMe will also increase.